Our 24-week study aims to evaluate LAM-001's safety, tolerability, and efficacy in 15 adults with advanced PAH. Primary endpoints include changes in peak oxygen uptake, among other hemodynamic metrics. https://lnkd.in/gJb4fcEg
OrphAI Therapeutics’ Post
More Relevant Posts
-
Our Phase 2a HuMAIN trial met the primary endpoint of weight reduction in patients w/ obesity-related heart failure. We're sharing detailed results highlighting our investigational therapy's potential to be the first disease-modifying #HFpEF treatment by enabling fat-specific weight loss while preserving muscle at this year's #HFSA Annual Scientific Meeting. Read more: https://bit.ly/4fArk2O
HuMAIN-Topline-Release_final.pdf
rivuspharma.com
To view or add a comment, sign in
-
Harold B. and Fatima Cody Stanford share crucial insights on GLP-1 receptor agonists (GLP-1 RAs) and their role in treating obesity, type 2 diabetes, and cardiovascular disease. 🚨 Key Points: 🔹 GLP-1 RAs help decrease cravings and manage obesity. 🔹 Each medication has unique benefits and potential side effects. 🔹 Accessibility and cost remain significant issues, especially for low-income and underrepresented groups. 💡 Understanding these medications empowers patients and healthcare providers, leading to better health outcomes. Let's continue advocating for equitable access and treating obesity with the dignity it deserves. #ObesityMatters #GLP1 #ObesityTreatment #EquityInHealth https://lnkd.in/gSyWiNYz
Safety, cost and more: The issues PCPs should consider when prescribing GLP-1s
healio.com
To view or add a comment, sign in
-
Co-founder & Co-CEO @ Embla | On a mission to eradicate reductive approaches to weight loss | Medical doctor | Writing about health & society
The recent publication of the Wegovy trial highlights a 20% reduction in cardiovascular events among high-risk groups 🚨. Yet, it requires treating 100 people to prevent just 1.5 events, coupled with a modest 8.5% weight loss 😮. Given the steep costs 💸, risk for weight regain, and the pharmaceutical industry's push for long-term drug dependence, one must question the true efficacy of these results 🤔. It's crucial to develop more sustainable usage strategies, including tapering methods. Why are we not getting more help here from Novo Nordisk and Eli Lilly 🌱? Henrik Rindel Gudbergsen Laust Wilster Axelsen Søren Seier Jesper Rode Olsen Josefine Balck Søren Kieffer Høj Nielsen Kine Stamp-Larsen
The big GLP-1 anti-obesity Wegovy randomized trial to reduce cardiovascular events was presented and published today. I've analyzed the results (which have been getting a lot of attention and hype) in the new Ground Truths https://lnkd.in/g3NcdUYS
The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events
erictopol.substack.com
To view or add a comment, sign in
-
EMA Approves Ocular Formulation of Bevacizumab for Macular Degeneration AMD (age-relatedmacular degeneration) is the most common cause of visual impairment and blindness in Europe, with a pooled annual incidence of late-stage disease of 1.4 per 1000 individuals, and numbers across Europe forecast to increase from 400,000 per year today to 700,000 per year by 2050. The number of people across the EU with any stage of AMD is predicted to rise from 67 million to 77 million in the same timeframe. https://lnkd.in/ddrrYVxj
EMA Approves Ocular Formulation of Bevacizumab
medscape.com
To view or add a comment, sign in
-
Professor of Medicine. Internist | Hypertensiologist | Nutritionist | Cardiovascular Risk | Digital Medicine | Biomedicine
REINFORCEMENT OF SCIENTIFIC EVIDENCE. 📍Eliminate LDLc as early as possible. 👉Long before CV events, 👉Eliminating LDLc early in patients with high CVR favors the avoidance of MACE, MACCE, PAD,…, 👉Facilitates any subsequent therapeutic intervention to compensate for Dyslipidemia. ❗️Primary prevention will always be the best intervention model that should happen as early as possible.
Eliminate LDL cholesterol after heart attack … but only for a while
academic.oup.com
To view or add a comment, sign in
-
AI startup advisor 'force multiplier' whose superpower is connecting and illuminating the dots that matter faster, better, smarter than you and 99.9% of people ;-)
THE FDA SAYS #OZEMPIC MIGHT BLOCK YOUR INTESTINES https://lnkd.in/gEEtzFUH Ozempic Can Cause Major Loss of Muscle Mass and Reduce Bone Density https://lnkd.in/g-3EgRV5 #Ozempic, #Wegovy, #Mounjaro Linked to Stomach Paralysis, Suicide and More https://lnkd.in/gdkTWxXs Ozempic side-effects of can be brutal https://lnkd.in/gnMWaAaF - Blurred vision - Inflammation of Pancreatitis and gallbladder issues - Severe stomach and digestive issues - Kidney problems (kidney failure) - serious allergic reactions - Ozempic face hollowed out, sagging, rapidly aged - Increased Risk of Thyroid Cancers Want to live longer? Influence your genes. https://lnkd.in/gxyC9ASz
The big GLP-1 anti-obesity Wegovy randomized trial to reduce cardiovascular events was presented and published today. I've analyzed the results (which have been getting a lot of attention and hype) in the new Ground Truths https://lnkd.in/g3NcdUYS
The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events
erictopol.substack.com
To view or add a comment, sign in
-
CEO & Founder at Savor Health | Managing and Preventing Chronic Disease Through Precision Nutrition Interventions, Cancer First
Great analysis of GLP-1 anti-obesity drug results for CVD events. As a lawyer, my dad used to tell me to "read the fine print". Well, Eric Topol, MD has here (and then some). REALLY important analysis of a recent large study of one of these drugs. 3 Key points - 1. results not as stellar as the hype with absolute reduction of CVD events 1.5 per 100, 3 years. 2. How do we ensure healthy weight loss and #nutrition to prevent loss of muscle and bone density. 3. What's the plan for step-down to less expensive, lower side effect drug?
The big GLP-1 anti-obesity Wegovy randomized trial to reduce cardiovascular events was presented and published today. I've analyzed the results (which have been getting a lot of attention and hype) in the new Ground Truths https://lnkd.in/g3NcdUYS
The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events
erictopol.substack.com
To view or add a comment, sign in
-
Human Type 1 and Type 2 diabetes in a dish.🔬 Today is the day!🎉 Come to our webinar to get a new insight on last development on unique translational assays to physiologically model Autoimmune type 1 diabetes and glucolipotoxicity Type 2 diabetes! To register and learn more about the event, click here: https://lnkd.in/eVdqfKeF #Diabetes, #Type1Diabetes, #Type2Diabetes, #PreclinicalResearch, #DiseaseModelling, #BioanalyticalTesting, #translational #assays, #PreClinical, #HumanCellDesign, #Mercodia, #EndoCβH5, #EndoCβH1, #Autoimmunetype1diabetes, #Tlymphocyte #killingassay, #glucolipotoxicity
To view or add a comment, sign in
-
-
AI startup advisor 'force multiplier' whose superpower is connecting and illuminating the dots that matter faster, better, smarter than you and 99.9% of people ;-)
Benefits of a plant-based diet: What happens to your body when you stop eating meat? https://lnkd.in/gyUq3Qq3 The #mediterraneandiet has stood the test of time for a reason: It works https://lnkd.in/ghxTMQRA 3 Amazing Things That Happen to Your Brain When You Follow the #MediterraneanDiet https://lnkd.in/gRq4VtHV These 8 habits could add up to 24 years to your life https://lnkd.in/g2ZVwEmj
The big GLP-1 anti-obesity Wegovy randomized trial to reduce cardiovascular events was presented and published today. I've analyzed the results (which have been getting a lot of attention and hype) in the new Ground Truths https://lnkd.in/g3NcdUYS
The Big Trial of a GLP-1 drug (Wegovy) to Reduce Major Cardiovascular Events
erictopol.substack.com
To view or add a comment, sign in